PharmiWeb.com - Global Pharma News & Resources
22-Jan-2019

Febrile Neutropenia - Pipeline Insight, 2019 - ResearchAndMarkets.com

The "Febrile Neutropenia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Febrile Neutropenia development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Febrile Neutropenia

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Febrile Neutropenia

The report assesses the active Febrile Neutropenia pipeline products by developmental stage, product type, molecule type, and administration route.

Topics Covered

1. Report Introduction

2. Febrile Neutropenia Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical & Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Featured

  • Apotex Inc.
  • Biogenomics Limited
  • Coherus BioSciences Inc.
  • Dr. Reddy's Laboratories Limited
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • Therapeutic Proteins International

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6fcktn/febrile?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005447/en/

Editor Details

Last Updated: 22-Jan-2019